EP
LBRX icon

Eversept Partners’s LB Pharmaceuticals LBRX Stock Holding History

Eversept Partners’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.96M Buy
183,663
+83,465
+83% +$2.45M 0.31% 62
2026
Q1 		$2.47M Buy
+100,198
New +$2.31M 0.13% 83

Other funds holding LBRX

Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Eversept Partners's LBRX Position: Q2 2026 in Review

Eversept Partners increased its LB Pharmaceuticals (LBRX) stake by 83% in Q2 2026, buying an estimated $2.45M and bringing the position to 183,663 shares worth $5.96M. The position accounts for 0.31% of the portfolio, ranked #62.

Eversept Partners first reported a position in LBRX in Q1 2026 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Eversept Partners held 183,663 shares of LB Pharmaceuticals worth $5.96M as of Q2 2026.
  • Eversept Partners bought 83,465 LB Pharmaceuticals shares in Q2 2026, an estimated $2.45M.
  • LB Pharmaceuticals made up 0.31% of Eversept Partners's portfolio in Q2 2026, its #62 holding.
  • Eversept Partners first reported a position in LB Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.